Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Incentives for biodefense countermeasure development.

Jason Matheny1, Michael Mair, Andrew Mulcahy

  • 1mmair@upmc-biosecurity.org

Biosecurity and Bioterrorism : Biodefense Strategy, Practice, and Science
|October 2, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Generics in Medicaid increased in price and shifted to larger manufacturers amid 2022-2023 amphetamine shortage.

Health affairs scholar·2026
Same author

Initial evaluation of using the AudioKey 2.0 app for cochlear implant usage data collection.

Scientific reports·2026
Same author

MODIFIED TECHNIQUE FOR SUTURED INTRAOCULAR LENS: ERRATUM.

Retina (Philadelphia, Pa.)·2026
Same author

Vitrectomy Following Pneumatic Retinopexy for Retinal Detachment: Indications and Outcomes.

Journal of vitreoretinal diseases·2026
Same author

Modified Technique for Sutured Intraocular Lens.

Retina (Philadelphia, Pa.)·2025
Same author

Choroidal thickness as a clinical marker in differentiating peripheral retinoschisis and retinal detachments.

European journal of ophthalmology·2025
Same journal

Re: optimization of interventions in ebola.

Biosecurity and bioterrorism : biodefense strategy, practice, and science·2014
Same journal

Enhancing US-Japan cooperation to combat antimicrobial resistance.

Biosecurity and bioterrorism : biodefense strategy, practice, and science·2014
Same journal

Interfacing a biosurveillance portal and an international network of institutional analysts to detect biological threats.

Biosecurity and bioterrorism : biodefense strategy, practice, and science·2014
Same journal

Regional collaboration among Urban Area Security Initiative regions: results of the Johns Hopkins urban area survey.

Biosecurity and bioterrorism : biodefense strategy, practice, and science·2014
Same journal

Travel bans will increase the damage wrought by ebola.

Biosecurity and bioterrorism : biodefense strategy, practice, and science·2014
Same journal

Global agenda, local health: including concepts of health security in preparedness programs at the jurisdictional level.

Biosecurity and bioterrorism : biodefense strategy, practice, and science·2014
See all related articles

Insufficient investment plagues biodefense countermeasure development. Expanding BioShield funding and creating priority review vouchers can incentivize biopharmaceutical industry engagement for public health security.

Area of Science:

  • Public Health Security
  • Biopharmaceutical Industry
  • Countermeasure Development

Background:

  • Limited availability of therapeutics and vaccines against biological threats leaves populations vulnerable.
  • Current U.S. policies have failed to adequately stimulate biopharmaceutical industry investment in biodefense products.

Purpose of the Study:

  • To examine the technical, regulatory, and market risks in biodefense countermeasure development.
  • To review existing and proposed federal incentives aimed at boosting industrial investment in biodefense.

Main Methods:

  • Analysis of risks inherent in developing countermeasures against biological threats.
  • Review of current and proposed U.S. federal incentive programs for biopharmaceutical companies.

Related Experiment Videos

Main Results:

  • Existing policies have not sufficiently encouraged biopharmaceutical industry investment in biodefense countermeasures.
  • Significant technical, regulatory, and market risks deter industry engagement.

Conclusions:

  • Congress should expand BioShield funding and grant the Department of Health and Human Services (HHS) flexibility to fund diverse countermeasures.
  • Implementing tradable priority review vouchers and exploring a government-managed 'Virtual Pharma' could enhance industry participation.